Literature DB >> 32166682

Ultrasound Features Improve Diagnostic Performance of Ovarian Cancer Predictors in Distinguishing Benign and Malignant Ovarian Tumors.

Yong-Ning Chen1,2, Fei Ma3, Ya-di Zhang2, Li Chen4, Chan-Yuan Li2, Shi-Peng Gong5.   

Abstract

To determine whether ultrasound features can improve the diagnostic performance of tumor markers in distinguishing ovarian tumors, we enrolled 719 patients diagnosed as having ovarian tumors at Nanfang Hospital from September 2014 to November 2016. Age, menopausal status, histopathology, the International Federation of Gynecology and Obstetrics (FIGO) stages, tumor biomarker levels, and detailed ultrasound reports of patients were collected. The area under the curve (AUC), sensitivity, and specificity of the bellow-mentioned predictors were analyzed using the receiver operating characteristic curve. Of the 719 patients, 531 had benign lesions, 119 had epithelial ovarian cancers (EOC), 44 had borderline ovarian tumors (BOT), and 25 had non-EOC. AUCs and the sensitivity of cancer antigen 125 (CA125), human epididymis-specific protein 4 (HE4), Risk of Ovarian Malignancy Algorithm (ROMA), Risk of Malignancy Index (RMI1), HE4 model, and Rajavithi-Ovarian Cancer Predictive Score (R-OPS) in the overall population were 0.792, 0.854, 0.856, 0.872, 0.893, 0.852, and 70.2%, 56.9%, 69.1%, 60.6%, 77.1%, 71.3%, respectively. For distinguishing EOC from benign tumors, the AUCs and sensitivity of the above mentioned predictors were 0.888, 0.946, 0.947, 0.949, 0.967, 0.966, and 84.0%, 79.8%, 87.4%, 84.9%, 90.8%, 89.1%, respectively. Their specificity in predicting benign diseases was 72.9%, 94.4%, 87.6%, 95.9%, 86.3%, 90.8%, respectively. Therefore, we consider biomarkers in combination with ultrasound features may improve the diagnostic performance in distinguishing malignant from benign ovarian tumors.

Entities:  

Keywords:  Rajavithi-Ovarian Cancer Predictive Score; Risk of Malignancy Index; Risk of Malignancy Index model; Risk of Ovarian Malignancy Algorithm; cancer antigen 125; human epididymis-specific protein 4; ovarian masses

Mesh:

Substances:

Year:  2020        PMID: 32166682     DOI: 10.1007/s11596-020-2163-7

Source DB:  PubMed          Journal:  Curr Med Sci        ISSN: 2523-899X


  28 in total

1.  A predictive model combining human epididymal protein 4 and radiologic features for the diagnosis of ovarian cancer.

Authors:  A Stiekema; C A R Lok; G G Kenter; W J van Driel; A D Vincent; C M Korse
Journal:  Gynecol Oncol       Date:  2014-01-10       Impact factor: 5.482

2.  CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use.

Authors:  M J Duffy; J M Bonfrer; J Kulpa; G J S Rustin; G Soletormos; G C Torre; M K Tuxen; M Zwirner
Journal:  Int J Gynecol Cancer       Date:  2005 Sep-Oct       Impact factor: 3.437

3.  Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas.

Authors:  Ronny Drapkin; Hans Henning von Horsten; Yafang Lin; Samuel C Mok; Christopher P Crum; William R Welch; Jonathan L Hecht
Journal:  Cancer Res       Date:  2005-03-15       Impact factor: 12.701

4.  Potential markers that complement expression of CA125 in epithelial ovarian cancer.

Authors:  Daniel G Rosen; Lin Wang; J Neeley Atkinson; Yinhua Yu; Karen H Lu; Eleftherios P Diamandis; Ingegerd Hellstrom; Samuel C Mok; Jinsong Liu; Robert C Bast
Journal:  Gynecol Oncol       Date:  2005-08-02       Impact factor: 5.482

5.  Modification of cut-off values for HE4, CA125 and the ROMA algorithm for early-stage epithelial ovarian cancer detection: Results from 1021 cases in South China.

Authors:  Ying Xu; Rihui Zhong; Jian He; Rui Ding; Haixiong Lin; Yawen Deng; Lijun Zhou; Xiaohui Li; Junyi Jiang; Yunwen Bao; Xiaohong Luo; Chaohui Duan
Journal:  Clin Biochem       Date:  2015-08-15       Impact factor: 3.281

6.  Influence of ovarian cancer risk status on the diagnostic performance of the serum biomarkers mesothelin, HE4, and CA125.

Authors:  Chirag A Shah; Kimberly A Lowe; Pamela Paley; Erin Wallace; Garnet L Anderson; Martin W McIntosh; M Robyn Andersen; Nathalie Scholler; Lindsay A Bergan; Jason D Thorpe; Nicole Urban; Charles W Drescher
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-05       Impact factor: 4.254

7.  Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.

Authors:  Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray
Journal:  Int J Cancer       Date:  2014-10-09       Impact factor: 7.396

8.  Determination of reference intervals of serum levels of human epididymis protein 4 (HE4) in Chinese women.

Authors:  Yaping Tian; Chuanxin Wang; Liming Cheng; Aimin Zhang; Wen Liu; Lin Guo; Huiming Ye; Yanchun Huang; Jing Chen; Xinyu Wen; Yuelei Xing; Guixi Zheng; Ziyong Sun; Huijun Li; Peng Zhang; Wanli Liu; Ying Chen; Zhongying Zhang; Yi Xu; Yishan Huo; Qishui Ou
Journal:  J Ovarian Res       Date:  2015-11-09       Impact factor: 4.234

9.  Usefulness of the HE4 biomarker as a second-line test in the assessment of suspicious ovarian tumors.

Authors:  Rafal Moszynski; Sebastian Szubert; Dariusz Szpurek; Slawomir Michalak; Joanna Krygowska; Stefan Sajdak
Journal:  Arch Gynecol Obstet       Date:  2013-05-31       Impact factor: 2.344

Review 10.  Assessment of adnexal masses using ultrasound: a practical review.

Authors:  Noam Smorgick; Ron Maymon
Journal:  Int J Womens Health       Date:  2014-09-23
View more
  3 in total

1.  Sonographic Assessment of Complex Ultrasound Morphology Adnexal Tumors in Pregnant Women with the Use of IOTA Simple Rules Risk and ADNEX Scoring Systems

Authors:  Artur Czekierdowski; Norbert Stachowicz; Agata Smoleń; Tomasz Kluz; Tomasz Łoziński; Andrzej Miturski; Janusz Kraczkowski
Journal:  Diagnostics (Basel)       Date:  2021-02-28

2.  Quantification of ovarian lesion and fallopian tube vasculature using optical-resolution photoacoustic microscopy.

Authors:  Xiandong Leng; Sitai Kou; Yixiao Lin; Andrea R Hagemann; Ian S Hagemann; Premal H Thaker; Lindsay M Kuroki; Carolyn K McCourt; David G Mutch; Cary Siegel; Matthew A Powell; Quing Zhu
Journal:  Sci Rep       Date:  2022-09-23       Impact factor: 4.996

3.  Efficacy of IOTA simple rules, O-RADS, and CA125 to distinguish benign and malignant adnexal masses.

Authors:  Wen Ting Xie; Yao Qin Wang; Zhi Sheng Xiang; Zhong Shi Du; Shi Xin Huang; Yi Jie Chen; Li Na Tang
Journal:  J Ovarian Res       Date:  2022-01-23       Impact factor: 4.234

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.